Unveiling the Clinicopathological Spectrum of Neuroendocrine Neoplasms in a Tertiary Care Setting
Authors/Creators
- 1. Assistant Professor Department of Pathology SCB Medical College and Hospital
- 2. Junior Resident, Department of Pathology, SCB Medical College and Hospital
- 3. Professor Kalyani Gouda, Department of Pathology, SCB Medical College and Hospital
- 4. Associate Professor, Department of Pathology, SCB Medical College and Hospital
- 5. Assistant Professor, Department of Pathology, SCB Medical College and Hospital
- 6. Senior Resident, Dept of Pathology, SCB Medical College and Hospital
- 7. Professor and HOD Department of Pathology, SCB Medical, College and Hospital
Description
Introduction: Neuroendocrine neoplasms are a heterogeneous group of malignancies showing various non-specific clinical symptoms, different morphological features, molecular involvement which makes it an important differential for all rapidly growing malignancies in our body since it has got a greater propensity to metastasize. The clinical symptoms depend on both the “neuro” and “endocrine” properties. Histopathologically, they form broader two groups of well differentiated and poorly differentiated neuroendocrine carcinomas and hence needs accurate grading depending on mitosis and Ki 67 counts. Hormonal and non-hormonal biomarkers like serum serotonin, urine 5-HIAA, gastrin and VIP are of equal relevance as well as histology. IHC markers for neuroendocrine neoplasms include synaptophysin, chromogranin, CD56 among others. Herein, we report all the neuroendocrine neoplasms detected in our setting for a period of 12 months and discuss extensively on the same. Materials and Methods: This is a retrospective cross sectional study carried out in the histopathology section of Department of Pathology, SCB Medical College and hospital, Cuttack. The total duration of the study was 12 months spanning from June 2023-June 2024. All the histopathological confirmed cases of neuroendocrine neoplasms based on recent 5th edition of WHO classification of endocrine and neuroendocrine tumors was analysed. Clinical data (age, sex, anatomical site) and histopathology along with IHC were studied. Results: We found a total of 12 patients diagnosed with neuroendocrine neoplasms involving various organs of the body. The mean age of patients was 51.83 years with age varying from 7yrs to 80 yrs. Majority were females with male to female ratio being 7:5. Majority of cases in our setting had involved adrenal glands with three cases diagnosed as pheochromocytoma followed by carotid body tumor (paraganglioma) and medullary carcinoma of thyroid, each with 2 cases respectively and rest all the organs presented with one case each i.e. pituitary, gastric, duodenal, rectum and appendix. Conclusion: In our cohort, the preponderance of pheochromocytomas was more followed by medullary carcinoma of thyroid and paraganglioma, with a notable female predominance. The diagnosis of neuroendocrine tumours necessitates meticulous radiological examination including USG, CT and MRI. Histopathology along with immunohistochemistry is imperative for arriving at a final diagnosis, accurate grading, and the formulation of an optimal management for the patient.
Abstract (English)
Introduction: Neuroendocrine neoplasms are a heterogeneous group of malignancies showing various non-specific clinical symptoms, different morphological features, molecular involvement which makes it an important differential for all rapidly growing malignancies in our body since it has got a greater propensity to metastasize. The clinical symptoms depend on both the “neuro” and “endocrine” properties. Histopathologically, they form broader two groups of well differentiated and poorly differentiated neuroendocrine carcinomas and hence needs accurate grading depending on mitosis and Ki 67 counts. Hormonal and non-hormonal biomarkers like serum serotonin, urine 5-HIAA, gastrin and VIP are of equal relevance as well as histology. IHC markers for neuroendocrine neoplasms include synaptophysin, chromogranin, CD56 among others. Herein, we report all the neuroendocrine neoplasms detected in our setting for a period of 12 months and discuss extensively on the same. Materials and Methods: This is a retrospective cross sectional study carried out in the histopathology section of Department of Pathology, SCB Medical College and hospital, Cuttack. The total duration of the study was 12 months spanning from June 2023-June 2024. All the histopathological confirmed cases of neuroendocrine neoplasms based on recent 5th edition of WHO classification of endocrine and neuroendocrine tumors was analysed. Clinical data (age, sex, anatomical site) and histopathology along with IHC were studied. Results: We found a total of 12 patients diagnosed with neuroendocrine neoplasms involving various organs of the body. The mean age of patients was 51.83 years with age varying from 7yrs to 80 yrs. Majority were females with male to female ratio being 7:5. Majority of cases in our setting had involved adrenal glands with three cases diagnosed as pheochromocytoma followed by carotid body tumor (paraganglioma) and medullary carcinoma of thyroid, each with 2 cases respectively and rest all the organs presented with one case each i.e. pituitary, gastric, duodenal, rectum and appendix. Conclusion: In our cohort, the preponderance of pheochromocytomas was more followed by medullary carcinoma of thyroid and paraganglioma, with a notable female predominance. The diagnosis of neuroendocrine tumours necessitates meticulous radiological examination including USG, CT and MRI. Histopathology along with immunohistochemistry is imperative for arriving at a final diagnosis, accurate grading, and the formulation of an optimal management for the patient.
Files
IJPCR,Vol16,Issue8,Article164.pdf
Files
(20.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:73e56393a16cb315ce0690d0ce8190e6
|
20.1 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-07-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue8,Article164.pdf
- Development Status
- Active
References
- 1. B. Oronsky, P. C. Ma, D. Morgensztern, and C. A. Carter, "Nothing but NET: a review of neuroendocrine tumors and carcinomas," Neoplasia, vol. 19, no. 12, pp. 991–1002, 2017.2. Silveira F, Basile ML, Kuga FS, Próspero JD, Paes RAP, Bernardi FDC. Neuroendocrine tumors: An epidemiological study of 250 cases at a tertiary hospital. Rev Assoc Med Bras (1992). 2017 Oct; 63(10):856-861. doi: 10.15 90/1806- 9282.63.10.856. PMID: 29267486. 3. Basu B, Sirohi B, and Corrie P (2010). Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer 17(1), R75-0. 4. Kaltsas GA, Besser GM, and Grossman AB (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25, 458–511 5. Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015 Feb 15; 121(4):589 97. 6. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015:92-103. doi: 10.14694/EdBook_AM.2015.35.92. PMID: 25993147. 7. Zandee WT, van der Zwan JM, de Herder WW, van Velthuysen MF. Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: ITS Guidelines Are a Good Start but Not Enough. Neuroendocrinology. 2020; 110(11- 12):994-1000. doi: 10.1159/ 000505920. Epub 2020 Jan 28. PMID: 31995804. 8. Samanta STN, Mehta SP, Patel TS, Jetly DH. Clinicopathological study of 100 cases of neuroendocrine neoplasms of the gastroenteropancreatic system: a tertiary cancer center experience. Indian J Med Paediatr Oncol. 2020; 41(3):340-4. 9. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022 Mar; 33(1):115-154. doi: 10.1007/s12022-022- 09708-2. Epub 2022 Mar 16. PMID: 35294 740. 10. Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of pituitary tumors. Endocr Pathol 33:6–26 17. 11. Mete O, Asa SL (2020) Structure, function, and morphology in the classification of pituitary neuroendocrine tumors: the importance of routine analysis of pituitary transcription fac tors. Endocr Pathol 31:330–336 12. Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L (2022) Overview of the 2022 WHO Classification of familial endocrine tumor syndromes. Endocr Pathol 33:197–227 13. Yangong, H.; Shi, C.; Shahbaz, M.; Shahbaz, M.; Shahbaz, M.; Zhengchuan, N.; Wang, J.; Liang, B.; Ruliang, F.; Gao, H.; et al. Diagnosis and Treatment Experience of Rectal Carcinoid (a Report of 312 Cases). Int. J. Surg. 2014 14. Jensen, R.T.; Berna, M.J.; Berna, M.J.; Berna, M.J.; Bingham, D.B.; Norton, J.A. Inherited Pancreatic Endocrine Tumor Syndromes: Advances in Molecular Pathogenesis, Diagnosis, Management, and Controversies. Cancer 2008, 113, 1807–1843. 15. Pinchot, S.N.; Holen, K.; Sippel, R.S.; Chen, H. Carcinoid Tumors. Oncologist 2008, 13, 1255– 1269. [CrossRef] 16. McCormick, D. Carcinoid Tumors and Syndrome. Gastroenterol. Nurs. 2002, 25, 105–111. 17. Vanoli A, La Rosa S, Klersy C, et al. Four neuroendocrine tumor types and neuroendocrine carcinoma of the duodenum: analysis of 203 cases. Neuroendocrinology. 2017; 104:112–25. 18. Bonds, M.; Rocha, F.G.; Rocha, F.G.; Rocha, F.G. Neuroendocrine Tumors of the Pancreatobiliary and Gastrointestinal Tracts. Surg. Clin. N. Am. 2020, 100, 635–648. 19. Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A (2022) Overview of the 2022 WHO Classification of paragan gliomas and pheochromocytomas. Endocr Pathol 33:90– 114.